MEDROL ACETATE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MEDROL ACETATE (MEDROL ACETATE).
Methylprednisolone acetate is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators including prostaglandins, leukotrienes, and cytokines.
| Metabolism | Hepatic metabolism primarily via CYP3A4 to inactive metabolites. |
| Excretion | Primarily renal (urinary) as inactive metabolites. Approximately 10-20% of the dose is excreted unchanged in urine. Biliary/fecal excretion accounts for <5% of the dose. |
| Half-life | Terminal elimination half-life of methylprednisolone (active form) is approximately 1.8–3.5 hours. The biological half-life (duration of HPA suppression) is longer: 18–36 hours. Clinical context: Short plasma half-life but prolonged tissue effects due to receptor binding. |
| Protein binding | Approximately 70–90% bound to cortisol-binding globulin (CBG) and albumin. Binding is saturable; at high doses, free fraction increases. |
| Volume of Distribution | 0.5–1.0 L/kg (methylprednisolone). Indicates extensive tissue penetration and distribution into extravascular spaces. |
| Bioavailability | Oral: 70–80% (methylprednisolone base). IM (methylprednisolone acetate): 80–100% (slow absorption from depot). For Medrol Acetate specifically, oral bioavailability is approximately 80%. |
| Onset of Action | IM injection: 24–48 hours (for crystalline suspension; slower absorption due to depot effect). Oral (tablets): 1–2 hours. |
| Duration of Action | IM depot: 1–2 weeks (single dose effect). Oral: Duration of anti-inflammatory effect 12–36 hours after a single dose, correlating with HPA suppression lasting 18–36 hours. |
| Molecular Weight | 416.51 |
4 to 48 mg orally once daily or in divided doses (e.g., 4 mg every 6 hours) depending on condition, typically starting at 4-48 mg/day. Also intramuscular (IM) as methylprednisolone acetate: 40-120 mg every 1-4 weeks. Intra-articular or soft tissue: 4-40 mg per injection depending on joint size.
| Dosage form | OINTMENT |
| Renal impairment | No specific dose adjustment required for renal impairment. Hemodialysis not expected to remove drug significantly. |
| Liver impairment | Child-Pugh A and B: No adjustment needed. Child-Pugh C: Manufacturer data insufficient; consider dose reduction due to potential decreased clearance. |
| Pediatric use | Oral: 0.05 to 2 mg/kg/day divided every 6-12 hours. IM: 0.03-0.2 mg/kg/day every 1-4 weeks. Intra-articular: 4-10 mg for small joints, 10-40 mg for large joints. Maximum oral: 60 mg/day. |
| Geriatric use | Initiate at lower end of adult dose (e.g., 4 mg daily). Monitor for hyperglycemia, osteoporosis, and cardiovascular effects. Use lowest effective dose for shortest duration. |
| 1st trimester | Corticosteroids like methylprednisolone acetate are associated with increased risk of cleft palate (1-2/1000) and intrauterine growth restriction. Use only if potential benefit justifies risk to fetus. |
| 2nd trimester | May cause fetal growth restriction and adrenal suppression. Prolonged use may impair fetal corticosteroid metabolism. Use lowest effective dose for shortest duration. |
| 3rd trimester | Can cause neonatal adrenal suppression if used near term. May precipitate premature labor. Avoid chronic use, especially in last 2 weeks. |
Clinical note
Comprehensive clinical and safety monograph for MEDROL ACETATE (MEDROL ACETATE).
| Placental transfer | Crosses placenta; undergoes placental metabolism to less active forms, but fetal concentrations are significant (fetal:maternal ratio ~0.3-0.5). |
| Breastfeeding | Methylprednisolone is excreted into breast milk in small amounts (milk-to-plasma ratio ~0.15). No adverse effects reported in infants except theoretical adrenal suppression at high doses. Use lowest effective dose; consider waiting 4 hours after dose to breastfeed to reduce exposure. Monitor infant for growth and development. |
■ FDA Black Box Warning
No FDA boxed warning for methylprednisolone acetate.
| Common Effects | Thinning of skin Increased risk of infection Reduction in bone density Weight gain Mood changes Upset stomach Behavioral changes |
| Serious Effects |
Systemic fungal infectionsHypersensitivity to methylprednisolone or any componentAdministration of live or live-attenuated vaccines (due to immunosuppression)Intrathecal administration (contraindicated due to risk of arachnoiditis)
| Precautions | Immunosuppression and increased risk of infections, Adrenal suppression with prolonged use or abrupt withdrawal, Osteoporosis with long-term use, Gastrointestinal perforation or bleeding, Cushing's syndrome with chronic therapy, Exacerbation of underlying infections or masking of signs, Thrombotic events, Avascular necrosis of femoral head, Anaphylaxis/hypersensitivity reactions, Growth suppression in children |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L2 (Safer) |
| Teratogenic Risk | Pregnancy Category C. First trimester: Increased risk of oral clefts (odds ratio 1.3-3.4). Second/third trimesters: Fetal adrenal suppression, intrauterine growth restriction, and oligohydramnios with prolonged use. |
| Fetal Monitoring | Maternal: Blood glucose, blood pressure, signs of infection. Fetal: Ultrasound for growth if prolonged use; consider fetal adrenal suppression monitoring. |
| Fertility Effects | May impair fertility in males (decreased sperm count/motility) and females (ovarian suppression). Effects are dose-dependent and generally reversible upon discontinuation. |
| Avoid grapefruit juice (may increase corticosteroid levels). Limit high-sodium foods to reduce fluid retention. Increase potassium intake (bananas, oranges) if hypokalemia risk. Alcohol may increase gastric irritation risk. |
| Clinical Pearls | MEDROL ACETATE is a methylprednisolone acetate injectable suspension for depot corticosteroid therapy. Avoid inadvertent intravenous administration due to risk of microembolism. Not for use in the treatment of traumatic brain injury (increased mortality). Administer deep IM into gluteal muscle; rotate sites. Do not inject into deltoid. May cause tendon rupture (especially Achilles) with fluoroquinolones. Monitor for adrenal suppression during taper. Contraindicated in systemic fungal infection or idiopathic thrombocytopenic purpura (IM use). |
| Patient Advice | Do not stop taking this medication suddenly; dose must be tapered under doctor's supervision. · Avoid receiving live vaccines while on this medication. · Report any signs of infection (fever, sore throat) or unusual bleeding/bruising. · Limit salt intake and eat potassium-rich foods if directed. · Keep all follow-up appointments for blood pressure and blood sugar monitoring. · Carry a medical alert card or wear a bracelet indicating corticosteroid use. |